See more : Champion Electric Metals Inc. (1QB0.F) Income Statement Analysis – Financial Results
Complete financial analysis of BioSyent Inc. (RX.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioSyent Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Joyware Electronics Co.,Ltd (300270.SZ) Income Statement Analysis – Financial Results
- Blue Ocean Acquisition Corp (BOCNW) Income Statement Analysis – Financial Results
- Superdry plc (SDRY.L) Income Statement Analysis – Financial Results
- Sanjivani Paranteral Limited. (SANJIVIN.BO) Income Statement Analysis – Financial Results
- Lekoil Limited (LEKOF) Income Statement Analysis – Financial Results
BioSyent Inc. (RX.V)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.biosyent.com
About BioSyent Inc.
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.59M | 27.93M | 28.62M | 22.33M | 21.42M | 21.53M | 20.76M | 17.92M | 15.39M | 12.21M | 7.80M | 5.02M | 2.81M | 1.68M | 1.03M | 1.10M | 1.10M | 1.51M | 748.52K | 711.04K | 812.84K | 532.02K | 665.93K | 887.31K | 800.00K | 700.00K | 700.00K |
| Cost of Revenue | 5.99M | 5.07M | 5.98M | 4.91M | 4.78M | 4.95M | 4.79M | 3.80M | 3.28M | 2.68M | 1.64M | 1.04M | 601.46K | 444.88K | 366.46K | 454.33K | 342.68K | 488.15K | 362.40K | 271.48K | 364.86K | 167.00K | 260.84K | 293.11K | 300.00K | 300.00K | 300.00K |
| Gross Profit | 25.60M | 22.86M | 22.64M | 17.42M | 16.65M | 16.57M | 15.97M | 14.13M | 12.11M | 9.53M | 6.16M | 3.98M | 2.21M | 1.24M | 663.45K | 647.66K | 761.65K | 1.03M | 386.12K | 439.56K | 447.98K | 365.03K | 405.10K | 594.20K | 500.00K | 400.00K | 400.00K |
| Gross Profit Ratio | 81.03% | 81.85% | 79.10% | 78.02% | 77.70% | 76.99% | 76.94% | 78.82% | 78.70% | 78.05% | 78.92% | 79.30% | 78.59% | 73.54% | 64.42% | 58.77% | 68.97% | 67.77% | 51.58% | 61.82% | 55.11% | 68.61% | 60.83% | 66.97% | 62.50% | 57.14% | 57.14% |
| Research & Development | 94.98K | 218.50K | 276.54K | 241.56K | 90.11K | 107.46K | 79.88K | 63.84K | 26.38K | 59.96K | 56.35K | 18.25K | 0.00 | 0.00 | 0.00 | 0.00 | 3.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.70M | 8.86M | 4.58M | 4.10M | 11.17M | 9.67M | 9.52M | 8.31M | 7.03M | 5.22M | 3.68M | 2.58M | 1.14M | 860.51K | 768.50K | 777.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.56M | 6.42M | 9.08M | 7.42M | 5.75M | 5.26M | 5.31M | 4.82M | 4.03M | 3.00M | 1.95M | 1.25M | 542.05K | 241.57K | 162.04K | 177.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.53M | 15.28M | 13.66M | 11.52M | 11.17M | 9.67M | 9.52M | 8.31M | 7.03M | 5.22M | 3.68M | 2.58M | 1.68M | 1.10M | 930.54K | 954.52K | 885.32K | 647.50K | 478.57K | 734.18K | 744.94K | 554.07K | 498.75K | 717.76K | 700.00K | 1.30M | 900.00K |
| Other Expenses | 506.74K | 451.00K | 457.11K | 537.24K | 0.00 | -5.26M | -5.31M | -4.82M | -4.03M | -3.00M | -1.95M | -1.25M | 10.54K | 7.01K | 33.67K | -17.50K | 34.45K | 22.02K | 7.95K | 18.04K | 148.08K | 246.61K | 361.02K | 217.40K | 200.00K | 200.00K | 100.00K |
| Operating Expenses | 18.13M | 15.95M | 14.39M | 12.30M | 11.26M | 9.78M | 9.60M | 8.37M | 7.05M | 5.28M | 3.74M | 2.60M | 1.69M | 1.18M | 945.89K | 937.02K | 922.81K | 669.52K | 486.52K | 752.22K | 893.02K | 800.68K | 859.77K | 935.16K | 900.00K | 1.50M | 1.00M |
| Cost & Expenses | 24.12M | 21.02M | 20.37M | 17.21M | 16.04M | 14.73M | 14.38M | 12.17M | 10.33M | 7.96M | 5.38M | 3.64M | 2.29M | 1.63M | 1.31M | 1.39M | 1.27M | 1.16M | 848.92K | 1.02M | 1.26M | 967.67K | 1.12M | 1.23M | 1.20M | 1.80M | 1.30M |
| Interest Income | 1.13M | 525.80K | 137.05K | 263.14K | 447.01K | 326.10K | 128.74K | 116.42K | 108.62K | 72.35K | 0.00 | 14.91K | 0.00 | 0.00 | 0.00 | 17.65K | 35.17K | 26.33K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 68.41K | 77.14K | 85.25K | 92.94K | 32.46K | 326.10K | 128.74K | 116.42K | 108.62K | 72.35K | 33.31K | 14.91K | 0.00 | 7.87K | 11.78K | 1.46K | 10.76K | 12.25K | 10.12K | 9.41K | 8.69K | 8.19K | 128.10K | 68.57K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 455.34K | 451.00K | 457.11K | 510.42K | 291.73K | 185.29K | 189.55K | 146.64K | 61.40K | 45.58K | 34.87K | 25.32K | 10.54K | 10.60K | 13.23K | 15.27K | 4.68K | 4.46K | 5.87K | 8.63K | 120.92K | 238.41K | 232.92K | 217.40K | 200.00K | 200.00K | 100.00K |
| EBITDA | 9.06M | 7.96M | 8.92M | 5.84M | 6.19M | 7.73M | 7.04M | 5.90M | 5.12M | 4.30M | 2.45M | 1.42M | 430.93K | 126.03K | -247.33K | -278.17K | -156.48K | 361.28K | -113.34K | -304.03K | -324.12K | -197.45K | -221.75K | -123.57K | -200.70K | -1.00M | -400.00K |
| EBITDA Ratio | 28.67% | 28.23% | 31.33% | 26.42% | 28.60% | 30.44% | 29.99% | 32.92% | 33.26% | 35.21% | 31.47% | 28.06% | 22.30% | 3.78% | -26.14% | -24.87% | -14.17% | 23.85% | -12.63% | -42.76% | -39.88% | -37.07% | -33.30% | -13.93% | -25.00% | -128.57% | -71.43% |
| Operating Income | 7.47M | 6.98M | 8.18M | 5.03M | 5.39M | 6.79M | 6.85M | 5.75M | 5.06M | 4.25M | 2.42M | 1.40M | 518.07K | 45.15K | -294.22K | -305.54K | -161.16K | 356.82K | -100.40K | -312.66K | -445.04K | -435.65K | -454.67K | -340.96K | -400.00K | -1.10M | -600.00K |
| Operating Income Ratio | 23.65% | 25.00% | 28.59% | 22.52% | 25.15% | 31.56% | 32.99% | 32.10% | 32.87% | 34.84% | 31.02% | 27.85% | 18.45% | 2.69% | -28.57% | -27.73% | -14.59% | 23.56% | -13.41% | -43.97% | -54.75% | -81.89% | -68.28% | -38.43% | -50.00% | -157.14% | -85.71% |
| Total Other Income/Expenses | 1.06M | 448.65K | 195.22K | 206.96K | 482.39K | 752.25K | 412.19K | 116.42K | 108.62K | 72.35K | 33.31K | 11.16K | -97.67K | 7.01K | 33.67K | 17.65K | 35.17K | -5.31K | 632.51K | 0.00 | 11.69K | 64.25K | 1.24M | 4.07K | 0.00 | 200.00K | -200.00K |
| Income Before Tax | 8.53M | 7.43M | 8.38M | 5.24M | 5.87M | 7.55M | 6.85M | 5.87M | 5.17M | 4.33M | 2.45M | 1.40M | 420.39K | 52.16K | -260.56K | 0.00 | -180.17K | 351.50K | 513.30K | 0.00 | -433.35K | -371.63K | 780.50K | -336.90K | 0.00 | -1.00M | -700.00K |
| Income Before Tax Ratio | 27.01% | 26.61% | 29.28% | 23.45% | 27.40% | 35.06% | 32.99% | 32.75% | 33.57% | 35.43% | 31.45% | 27.85% | 14.97% | 3.10% | -25.30% | 0.00% | -16.31% | 23.21% | 68.58% | 0.00% | -53.31% | -69.85% | 117.20% | -37.97% | 0.00% | -142.86% | -100.00% |
| Income Tax Expense | 2.07M | 1.97M | 2.10M | 1.44M | 1.50M | 1.84M | 1.64M | 1.56M | 1.40M | 1.17M | 524.81K | -142.20K | 97.67K | 7.87K | 11.78K | -1.46K | -54.18K | -31.64K | 8.04K | 0.00 | -18.48K | 0.00 | 0.00 | 68.57K | 100.00K | 100.00K | -100.00K |
| Net Income | 6.46M | 5.46M | 6.28M | 3.80M | 4.37M | 5.71M | 5.21M | 4.31M | 3.76M | 3.15M | 1.93M | 1.54M | 420.39K | 52.16K | -260.56K | -287.89K | -125.99K | 383.15K | 505.26K | -312.66K | -414.88K | -371.63K | 780.50K | -405.47K | -500.00K | -1.10M | -600.00K |
| Net Income Ratio | 20.45% | 19.55% | 21.95% | 16.99% | 20.39% | 26.50% | 25.08% | 24.05% | 24.47% | 25.83% | 24.72% | 30.68% | 14.97% | 3.10% | -25.30% | -26.12% | -11.41% | 25.30% | 67.50% | -43.97% | -51.04% | -69.85% | 117.20% | -45.70% | -62.50% | -157.14% | -85.71% |
| EPS | 0.54 | 0.44 | 0.50 | 0.29 | 0.31 | 0.39 | 0.36 | 0.30 | 0.27 | 0.23 | 0.14 | 0.12 | 0.03 | 0.00 | -0.02 | -0.02 | -0.01 | 0.03 | 0.04 | -0.02 | -0.04 | -0.04 | 0.09 | -0.04 | -0.06 | -0.16 | -0.09 |
| EPS Diluted | 0.53 | 0.44 | 0.49 | 0.29 | 0.31 | 0.39 | 0.36 | 0.30 | 0.26 | 0.22 | 0.13 | 0.11 | 0.03 | 0.00 | -0.02 | -0.02 | -0.01 | 0.03 | 0.04 | -0.02 | -0.04 | -0.04 | 0.09 | -0.04 | -0.06 | -0.16 | -0.09 |
| Weighted Avg Shares Out | 11.95M | 12.30M | 12.69M | 13.00M | 13.95M | 14.51M | 14.46M | 14.37M | 13.87M | 13.68M | 13.51M | 12.86M | 12.52M | 12.49M | 12.49M | 12.49M | 12.33M | 12.32M | 12.32M | 15.63M | 11.60M | 9.17M | 9.17M | 9.92M | 8.33M | 6.88M | 6.67M |
| Weighted Avg Shares Out (Dil) | 12.17M | 12.54M | 12.87M | 13.09M | 13.95M | 14.54M | 14.59M | 14.51M | 14.44M | 14.36M | 14.40M | 14.16M | 13.23M | 12.49M | 12.49M | 12.49M | 12.33M | 12.80M | 12.32M | 15.63M | 11.60M | 9.17M | 9.17M | 9.92M | 8.33M | 6.88M | 6.67M |
Source: https://incomestatements.info
Category: Stock Reports